ONL Therapeutics Awarded $1.37 Million SBIR Phase II Grant
ANN ARBOR - ONL Therapeutics, a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, Wednesday announced it has been awarded a $1.37 million Small Business Innovation Research Phase II contract from the National Eye Institute to advance development of ONL101, the company?s lead therapeutic candidate. ONL101 is a first-in-class